Below are some updates and developments from the past week.
Browsing: ron bentsur
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.